BiotechTube

Frexalimab + Teriflunomide + Placebo infusion + Placebo tablet + MRI contrast-enhancing agents + Cholestyramine + Activated charcoal

Phase 3Recruiting
0 views this week 0 watching⚡ Active🧠Featured in Neuroscience Pipeline Watch
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Multiple Sclerosis

Conditions

Multiple Sclerosis

Trial Timeline

Dec 13, 2023 → May 6, 2027

NCT ID
NCT06141473

About Frexalimab + Teriflunomide + Placebo infusion + Placebo tablet + MRI contrast-enhancing agents + Cholestyramine + Activated charcoal

Frexalimab + Teriflunomide + Placebo infusion + Placebo tablet + MRI contrast-enhancing agents + Cholestyramine + Activated charcoal is a phase 3 stage product being developed by Sanofi for Multiple Sclerosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06141473. Target conditions include Multiple Sclerosis.

What happened to similar drugs?

20 of 20 similar drugs in Multiple Sclerosis were approved

Approved (20) Terminated (0) Active (0)
✅Mirabegron + PlaceboAstellas PharmaApproved
✅Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + PlaceboAstellas PharmaApproved
✅TeclistamabJohnson & JohnsonApproved
✅BortezomibJohnson & JohnsonApproved
✅DaratumumabJohnson & JohnsonApproved
✅Mavenclad®MerckApproved
✅Mavenclad®MerckApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06141473Phase 3Recruiting

Competing Products

20 competing products in Multiple Sclerosis

See all competitors
ProductCompanyStageHype Score
Placebo + PirtobrutinibEli LillyPhase 2
27
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomideEli LillyPhase 1/2
32
NEX-20ANanexa ABPhase 1
23
agenT-797MiNK TherapeuticsPhase 1
19
Duloxetine Hydrochloride (HCI) + PlaceboEli LillyPhase 3
40
TemferonGenenta SciencePhase 1/2
14
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3
47
CT-P53 + US-Ocrevus + EU-OcrevusCelltrionPhase 3
47
CS-0777 tablets + CS-0777 tablets + CS-0777 tabletsDaiichi SankyoPhase 1
29
ASP7487, Velcade, DexamethasoneAstellas PharmaPhase 1/2
24
PHE885NovartisPhase 2
27
Mirabegron + PlaceboAstellas PharmaApproved
43
Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + PlaceboAstellas PharmaApproved
43
Denileukin Diftitox (Ontak)EisaiPhase 1
21
PalonosetronEisaiPhase 2
35
BIW-8962Kyowa KirinPhase 1
21
KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor)Kyowa KirinPhase 2
35
KW-2478 + BortezomibKyowa KirinPhase 1/2
32
ONO-2808 + PlaceboOno PharmaceuticalPhase 2
39
KW-2478Kyowa KirinPhase 1
29